Shots:

• The company presented the new data of its T-cell engaging bispecific Abs- mosunetuzumab- glofitamab and cevostamab at ASH 2020- demonstrating encouraging activity across multiple types of blood cancer
• Roche divulges that its mosunetuzumab & glofitamab showed promising responses across multiple types of NHL- including R/R FL & DLBCL- reinforcing from the P-I/Ib GO29781 study results in R/R FL- that showed 51.6% of patients achieved a CR when treated with mosunetuzumab
• Beyond r/r setting- mosunetuzumab & glofitamab are also being evaluated in 1L DLBCL. Additionally- Roche has presented the data of cevostamab that showed a 53% ORR rate in heavily pre-treated patients with MM

 ­ Ref: GlobeNewswire | Image: Roche